PMID: 25774823Mar 17, 2015Paper

Clinical and urodynamic results of alpha-blocker drug treatment in patients with lower urinary tract symptoms and benign prostatic hyperplasia

Archivos españoles de urología
J Salinas, Grupo URAL

Abstract

To analyse the improvement in both symptoms (IPSS questionnaire) and uroflowmetry parameters (Qmax) after treatment with different alpha-blockers in patients with LUTS and BPH. The efficacy of alpha-blocker treatment on urodynamic parameters was also analysed in some patients. An epidemiological, retrospective, multi-centre, and observational study. Twenty-five (24) Spanish healthcare centres recruited 443 patients with LUTS and BPH, and no other concurrent urological disease, they were on treatment with alpha-blockers. The study variables (demographic, physical examination, IPSS, and urodynamic) were collected retrospectively at start of the study (at least 12 weeks after the start of treatment). Two-tailed statistical tests were performed with a 5% significance level using a SAS statistical software package version 9.0. The IPSS score improved after 12 weeks of treatment (p<0.0001). The quality of life perception significantly improved (p<0.0001). The voiding volume and Qmax increased (p<0.0001) and the post-void residual urine decreased (p<0.0001) after treatment both in patients with moderate and severe symptoms. Other than filling pressure and involuntary contraction amplitude (p>0.05), all cystomanometry parameters improv...Continue Reading

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.